A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.

Timeline

Start

2022-12-29

Primary completion

2026-12

Completion

2026-12

Drugs

Indications